Abstract
Somatically acquired, activating mutations of GNAS, the gene encoding the stimulatory G-protein Gsα subunit, have been identified in kidney, thyroid, pituitary, leydig cell, adrenocortical and, more recently, in colorectal tumours, suggesting that mutations such as R201C may be oncogenic in these tissues. To study the role of GNAS in intestinal tumourigenesis, we placed GNAS R201C under the control of the A33-antigen promoter (Gpa33), which is almost exclusively expressed in the intestines. The GNAS R201C mutation has been shown to result in the constitutive activation of Gsα and adenylate cyclase and to lead to the autonomous synthesis of cyclic adenosine monophosphate (cAMP). Gpa33tm1(GnasR201C)Wtsi/+ mice showed significantly elevated cAMP levels and a compensatory upregulation of cAMP-specific phosphodiesterases in the intestinal epithelium. GNAS R201C alone was not sufficient to induce tumourigenesis by 12 months, but there was a significant increase in adenoma formation when Gpa33tm1(GnasR201C)Wtsi/+ mice were bred onto an ApcMin/+ background. GNAS R201C expression was associated with elevated expression of Wnt and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase (ERK1/2 MAPK) pathway target genes, increased phosphorylation of ERK1/2 MAPK and increased immunostaining for the proliferation marker Ki67. Furthermore, the effects of GNAS R201C on the Wnt pathway were additive to the inactivation of Apc. Our data strongly suggest that activating mutations of GNAS cooperate with inactivation of APC and are likely to contribute to colorectal tumourigenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abud HE, Johnstone CN, Tebbutt NC, Heath JK . (2000). The murine A33 antigen is expressed at two distinct sites during development, the ICM of the blastocyst and the intestinal epithelium. Mech Dev 98: 111–114.
Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M et al. (2003). Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 63: 728–734.
Barbacid M . (1987). ras genes. Annu Rev Biochem 56: 779–827.
Bos JL . (1989). ras oncogenes in human cancer: a review. Cancer Res 49: 4682–4689.
Brink M, de Goeij AF, Weijenberg MP, Roemen GM, Lentjes MH, Pachen MM et al. (2003). K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 24: 703–710.
Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS . (2005). Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310: 1504–1510.
Chen CJ, Liu JY, Cheng SN, Chang FW, Yuh YS . (2004). McCune-Albright syndrome associated with pituitary microadenoma: patient report. J Pediatr Endocrinol Metab 17: 365–369.
Collins MT, Sarlis NJ, Merino MJ, Monroe J, Crawford SE, Krakoff JA et al. (2003). Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations. J Clin Endocrinol Metab 88: 4413–4417.
Conti M, Beavo J . (2007). Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76: 481–511.
Dietrich WF, Lander ES, Smith JS, Moser AR, Gould KA, Luongo C et al. (1993). Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell 75: 631–639.
Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN . (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183–1188.
Fragoso MC, Domenice S, Latronico AC, Martin RM, Pereira MA, Zerbini MC et al. (2003). Cushing's syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hyperplasia due to activating mutations of GNAS1 gene. J Clin Endocrinol Metab 88: 2147–2151.
Fragoso MC, Latronico AC, Carvalho FM, Zerbini MC, Marcondes JA, Araujo LM et al. (1998). Activating mutation of the stimulatory G protein (gsp) as a putative cause of ovarian and testicular human stromal Leydig cell tumors. J Clin Endocrinol Metab 83: 2074–2078.
Giles RH, van Es JH, Clevers H . (2003). Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653: 1–24.
Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN et al. (2008). Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 40: 600–608.
Happle R . (1986). The McCune-Albright syndrome: a lethal gene surviving by mosaicism. Clin Genet 29: 321–324.
Hayward BE, Barlier A, Korbonits M, Grossman AB, Jacquet P, Enjalbert A et al. (2001). Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly. J Clin Invest 107: R31–R36.
Horvath A, Boikos S, Giatzakis C, Robinson-White A, Groussin L, Griffin KJ et al. (2006). A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet 38: 794–800.
Horvath A, Giatzakis C, Tsang K, Greene E, Osorio P, Boikos S et al. (2008). A cAMP-specific phosphodiesterase (PDE8B) that is mutated in adrenal hyperplasia is expressed widely in human and mouse tissues: a novel PDE8B isoform in human adrenal cortex. Eur J Hum Genet 16: 1245–1253.
Houslay MD, Milligan G . (1997). Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem Sci 22: 217–224.
Johnstone CN, Tebbutt NC, Abud HE, White SJ, Stenvers KL, Hall NE et al. (2000). Characterization of mouse A33 antigen, a definitive marker for basolateral surfaces of intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 279: G500–G510.
Kalfa N, Lumbroso S, Boulle N, Guiter J, Soustelle L, Costa P et al. (2006). Activating mutations of Gsalpha in kidney cancer. J Urol 176: 891–895.
Kirk JM, Brain CE, Carson DJ, Hyde JC, Grant DB . (1999). Cushing's syndrome caused by nodular adrenal hyperplasia in children with McCune-Albright syndrome. J Pediatr 134: 789–792.
Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS et al. (2000). Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 26: 89–92.
Kotoula V, Sozopoulos E, Litsiou H, Fanourakis G, Koletsa T, Voutsinas G et al. (2009). Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Endocr Relat Cancer 16: 565–572.
Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L . (1989). GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340: 692–696.
Levy DB, Smith KJ, Beazer-Barclay Y, Hamilton SR, Vogelstein B, Kinzler KW . (1994). Inactivation of both APC alleles in human and mouse tumors. Cancer Res 54: 5953–5958.
Livak KJ, Schmittgen TD . (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408.
Luo F, Brooks DG, Ye H, Hamoudi R, Poulogiannis G, Patek CE et al. (2007). Conditional expression of mutated K-ras accelerates intestinal tumorigenesis in Msh2-deficient mice. Oncogene 26: 4415–4427.
Luo F, Brooks DG, Ye H, Hamoudi R, Poulogiannis G, Patek CE et al. (2009). Mutated K-ras(Asp12) promotes tumourigenesis in Apc(Min) mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways. Int J Exp Pathol 90: 558–574.
MacMahon HE . (1971). Albright's syndrome—thirty years later (polyostotic fibrous dysplasia). Pathol Annu 6: 81–146.
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F et al. (2007). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263–1284.
Nishihara H, Hwang M, Kizaka-Kondoh S, Eckmann L, Insel PA . (2004). Cyclic AMP promotes cAMP-responsive element-binding protein-dependent induction of cellular inhibitor of apoptosis protein-2 and suppresses apoptosis of colon cancer cells through ERK1/2 and p38 MAPK. J Biol Chem 279: 26176–26183.
Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A et al. (1991). Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253: 665–669.
Orner GA, Dashwood WM, Blum CA, Diaz GD, Li Q, Al-Fageeh M et al. (2002). Response of Apc(min) and A33 (delta N beta-cat) mutant mice to treatment with tea, sulindac, and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Mutat Res 506–507: 121–127.
Palos-Paz F, Perez-Guerra O, Cameselle-Teijeiro J, Rueda-Chimeno C, Barreiro-Morandeira F, Lado-Abeal J et al. (2008). Prevalence of mutations in TSHR, GNAS, PRKAR1A and RAS genes in a large series of toxic thyroid adenomas from Galicia, an iodine-deficient area in NW Spain. Eur J Endocrinol 159: 623–631.
Plagge A, Kelsey G, Germain-Lee EL . (2008). Physiological functions of the imprinted Gnas locus and its protein variants Galpha(s) and XLalpha(s) in human and mouse. J Endocrinol 196: 193–214.
Radtke F, Clevers H . (2005). Self-renewal and cancer of the gut: two sides of a coin. Science 307: 1904–1909.
Rudolph JA, Poccia JL, Cohen MB . (2004). Cyclic AMP activation of the extracellular signal-regulated kinases 1 and 2: implications for intestinal cell survival through the transient inhibition of apoptosis. J Biol Chem 279: 14828–14834.
Sansom OJ, Meniel V, Wilkins JA, Cole AM, Oien KA, Marsh V et al. (2006). Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc Natl Acad Sci USA 103: 14122–14127.
Sieber OM, Tomlinson IP, Lamlum H . (2000). The adenomatous polyposis coli (APC) tumour suppressor—genetics, function and disease. Mol Med Today 6: 462–469.
Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science 314: 268–274.
Stork PJ, Schmitt JM . (2002). Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 12: 258–266.
Stratakis CA . (2003). Genetics of adrenocortical tumors: gatekeepers, landscapers and conductors in symphony. Trends Endocrinol Metab 14: 404–410.
Su H, Mills AA, Wang X, Bradley A . (2002). A targeted X-linked CMV-Cre line. Genesis 32: 187–188.
Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C et al. (1992). Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256: 668–670.
Taboada GF, Tabet AL, Naves LA, de Carvalho DP, Gadelha MR . (2009). Prevalence of gsp oncogene in somatotropinomas and clinically non-functioning pituitary adenomas: our experience. Pituitary 12: 165–169.
Taketo MM . (2006). Mouse models of gastrointestinal tumors. Cancer Sci 97: 355–361.
Weinstein LS, Liu J, Sakamoto A, Xie T, Chen M . (2004). Minireview: GNAS: normal and abnormal functions. Endocrinology 145: 5459–5464.
Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM . (1991). Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325: 1688–1695.
Wilkins JA, Sansom OJ . (2008). C-Myc is a critical mediator of the phenotypes of Apc loss in the intestine. Cancer Res 68: 4963–4966.
Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ et al. (2007). The genomic landscapes of human breast and colorectal cancers. Science 318: 1108–1113.
Yang GC, Yao JL, Feiner HD, Roses DF, Kumar A, Mulder JE . (1999). Lipid-rich follicular carcinoma of the thyroid in a patient with McCune-Albright syndrome. Mod Pathol 12: 969–973.
Zhang T, Otevrel T, Gao Z, Gao Z, Ehrlich SM, Fields JZ et al. (2001). Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61: 8664–8667.
Acknowledgements
Work in the DJ Adams Laboratory and the MJ Arends Laboratory is funded by Cancer Research UK (CR-UK) and the Wellcome Trust. We thank Dr Mattias Ernst for providing the Gpa33 targeting vector.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Wilson, C., McIntyre, R., Arends, M. et al. The activating mutation R201C in GNAS promotes intestinal tumourigenesis in ApcMin/+ mice through activation of Wnt and ERK1/2 MAPK pathways. Oncogene 29, 4567–4575 (2010). https://doi.org/10.1038/onc.2010.202
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2010.202
Keywords
This article is cited by
-
Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
npj Genomic Medicine (2023)
-
Activation of melanocortin-1 receptor signaling in melanoma cells impairs T cell infiltration to dampen antitumor immunity
Nature Communications (2023)
-
A recurrent somatic missense mutation in GNAS gene identified in familial thyroid follicular cell carcinomas in German longhaired pointer dogs
BMC Genomics (2022)
-
Tubulovillous adenoma with high-grade dysplasia of the vulva harboring high tumor mutational burden and cancer-associated mutations: a case report
Diagnostic Pathology (2022)
-
Oncogene addiction to GNAS in GNASR201 mutant tumors
Oncogene (2022)